Unbiased estimation in two-stage adaptive enrichment designs
两阶段自适应富集设计中的无偏估计AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要围绕临床试验中经自适应亚群选择后的处理效应估计及其选择偏差展开。
两阶段自适应富集设计中的无偏估计AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Recent advances in biomedical research have identified an increasing number of biomarkers associated with heterogeneity in patient responses to medical treatments. When a treatment is suspected to benefit certain patient subpopulations, adaptive enrichment designs may be more efficient and ethical. In such designs, an interim analysis is incorporated during the trial to select patient subpopulations for which the experimental treatment appears promising, according to predefined subpopulation selection rules. However, data-dependent selection can induce selection bias, causing conventional maximum likelihood estimators (MLEs) to overestimate the treatment effect in the selected patient subgroup. Existing inference methods for addressing this bias are typically rule-specific, highlighting the need for an estimation framework that accommodate a broader class of subpopulation selection rules. In this work, we define a general class of subpopulation selection rules based on the sample space partition condition and provide a systematic derivation that yields a unified formula for the Uniformly Minimum Variance Conditional Unbiased Estimator (UMVCUE). This generality allows our formulation to encompass a wide spectrum of adaptive enrichment designs, eliminating the necessity for case-specific derivations for each new design. Extensive simulations confirm the unbiasedness of the proposed UMVCUE, ensuring that therapeutic benefits are not overestimated. By bridging the gap between flexible interim subpopulation selection and rigorous statistical inference, our framework has the potential to facilitate the implementation of diverse subpopulation selection rules with greater ease in real-world trials and promote more efficient and ethical drug development.